Overexpression of CD200 is related with the chemotherapy resistance of advanced cervical cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057436

Enrollment

Unknown

Registered

2022-03-12

Start date

2022-02-28

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

A:No

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Cervical cancer patients with IVB disease and persistent disease; 2. Or patients with recurrent cervix treated by chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Only receive one cycle of chemotherapy; 2. Patients with neuroendocrine histopathology or other diseases that affect the level of blood components (such as blood malignancies, infectious diseases or autoimmune diseases).

Design outcomes

Primary

Measure	Time frame
CD200;	—

Countries

China

Contacts

Public ContactTang Qing

Affiliated Yantai Yuhuangding Hospital,Medical College of Qingdao University

tangqing0535@163.com+86 13562532206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026